Académique Documents
Professionnel Documents
Culture Documents
Follicular Lymphoma Treatment Market is expected to reach US$ XXBn by 2026 from US$ XXBn
in 2017 at a CAGRof XX%Lymphoma is cancer of lymphatic system, which disturbs the cells of
the immune system known as lymphocytes causes’ growth of the cells. Lymphocytes are the
white blood cells which protect the body from the infection. It is of two types one is Non-
Hodgkin and another is Hodgkin lymphoma. Follicular lymphoma is a type of Non-Hodgkin
Lymphoma which affects the lymphocytes. Follicular lymphoma has symptoms like increase of
the lymph nodes in the neck, shortness of breath, weight loss, night sweats. The rising
prevalence of follicular lymphoma, family history of the disease, and increasing incidence of
blood disorders worldwide are proving to be the key driving factors forFollicular Lymphoma
Treatment Market. In addition, increasing research and development activities for the innovation
of newer drugs and treatment methods and technological advancements in disease diagnosis
would further fuel the follicular lymphoma market in the near future. However, the probable
restraints like strict regulatory requirements for drug approval, high treatment cost, and adverse
effects associated with different treatment methods should also be taken intoaccount.
Follicular Lymphoma Treatment Market is segmented by Treatment Type, End User, and
Geography. The key factors which drive the global follicular lymphoma treatment market in the
forecast period are increasing the occurrence of follicular lymphoma, Genetic disease, and
growth rate of blood disorders at a global level. However, firm regulatory requirements for drug
approval, huge treatment cost, and adverse results related to different treatment methods may
restrain the market. Furthermore, new therapies like monoclonal antibodies with government
initiatives for cancer management are expected to boost the market. Radiation and
chemotherapy are currently a reactive treatment for follicular lymphoma. However, radiation
alone is used for the treatment of follicular lymphoma in maximum cases. In complex cases,
chemotherapy alone is used for the treatment of follicular lymphoma. Moreover, Targeted
Therapy is better than chemotherapy and Radiation, as they act directly by targeting tumour
cells. Geographically North America follicular lymphoma treatment market is is expected to hold
maximum market share during forecast period huge growth in the occurrence of thedisease in
the region, mainly in the U.S. The market in Europe is also expected to expand significantly
during the estimated period, because of firm health care infrastructure and rise in the
occurrence of follicular lymphoma in the region. Some of the important players working at a
global level contain Roche, Spectrum Pharmaceuticals, Johnson and Johnson, CTI Biopharma,
Celgene, AbbVie Inc., Novartis, Amgen, Merck & Co. (MRK), Seattle Genetics, Pharmacyclics/
Bristol-Myers Squibb (BMY), and Bayer AG’S. In 2017, Bayer AG’s has launched the advanced
drug, Aliqopa, also known as copanlisib, which is a kinase inhibitor which block certain enzymes
responsible in cell growth.
(North America, Europe, Asia Pacific, Middle East & Africa and Latin America)
This Report Is Submitted By @Maximize Market Research Company
Contact info:
Name: Lumawant Godage
Organization: MAXIMIZE MARKETRESEARCHPVT.LTD.
Email: sales@maximizemarketresearch.com
Address: Omkar Heights, Sinhagad Road, Manik Baug, Vadgaon Bk, Pune, Maharashtra 411051,
India.
Contact: +919607195908